GlaxoSmithKline: A FTSE 100 Dividend-Raising Star

Published in Company Comment on 14 November 2012

Can GlaxoSmithKline's (LSE: GSK) dividend continue to beat the wider market?

In an outcome that's tough on investors, the FTSE 100 (UKX) has failed to deliver a rising dividend payout over the last few years.

Just look at the iShares FTSE 100 ETF (LSE: ISF), for example. This is an exchange-traded fund that tracks the benchmark index, and we can see the aggregate payment from Britain's top 100 companies has yet to regain its pre-recession peak:

Year20072008200920102011
Dividend per share19.1p20.2p17.1p16.2p18.1p

But some companies within London's premier index have performed well on dividends, despite these austere times, and this series aims to seek them out. One such name is GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US).

The big question is can the company's dividend continue to out-perform its index. Let's take a closer look.

GlaxoSmithKline is one of the world's largest pharmaceutical companies. With the shares at 1347p, the market cap is £66,346 million. This table summarises the firm's recent financial record:

Year20072008200920102011
Revenue (£m)22,71624,35228,36828,39227,387
Net cash from operations (£m)61617205784167976250
Adjusted earnings per share99.1p104.7p121.2p53.9p114.1p
Dividend per share53p57p61p65p70p

So, the dividend has increased by 32% during the last five years -- equivalent to a 7.2% compound annual growth rate.

UK-based GlaxoSmithKline describes itself as one of the world's leading research-based pharmaceutical and healthcare companies with over 97,000 employees spread across more than 100 countries.

The firm makes prescription and over-the-counter medicines, vaccines, and oral and nutritional healthcare products to treat, amongst other things, major disease areas such as asthma, virus control, infections, mental health, diabetes, cardiovascular and digestive conditions. It's also developing new treatments for cancer.

Despite a flat US market and a 4% decline in revenues from Europe last year, strong sales growth from emerging markets continued. However, the company's largest markets are the US, which delivers around 32% of revenues and Europe, which generates about 30%. Emerging markets, although growing at a fair clip, only delivered about 19% of revenues last year, followed by Japan at 8%, Asia Pacific at 7% and other countries, which supplied the remaining 4%.

Cash flow seems constant: medicine has great repeat-purchase credentials. That's why Glaxo attracts income investors so consistently.

GlaxoSmithKline's dividend growth score

I analyse four different features of a company to judge whether its dividend can continue to rise:

1. Dividend cover: adjusted earnings covered the last dividend 1.63 times. 3/5

2. Net cash or debt: net gearing of 124% with borrowings about 1.25 times earnings. 3/5

3. Cash flow: cash flow supports earnings. 4/5

4. Outlook and recent trading: mixed recent trading and a cautiously positive outlook. 4/5

Overall, I score Glaxo 14 out of 20, which encourages me to believe the firm's dividend can continue to out-pace dividends from the FTSE 100.

Foolish summary

Despite recent mixed trading, Glaxo has a decent late-stage pipeline of products, which encourage the cautiously positive outlook. Pockets of perky growth around the world, and reliable repeat business in other markets, ensure a robust flow of cash. It's encouraging to see the company so committed to shareholder returns, which bodes well for the prospects of the dividend.

Right now, the forecast full-year dividend is 78.22p per share, which supports a possible income of 5.8%. That looks attractive to me.

GlaxoSmithKline is one of several dividend out-performers on the London stock exchange. There's one man who's as keen as I am to find, and invest, in them. I suggest you read all about his best investment ideas now in this free, time-limited report, while you have the chance: 8 Income Plays Held By Britain's Super Investor. This free report analyses the £20 billion portfolio of legendary high-yield expert Neil Woodford. Click here to discover his favourite dividend opportunities with good growth potential.

> Kevin does not own any shares mentioned in this article.

Share & subscribe

Comments

The opinions expressed here are those of the individual writers and are not representative of The Motley Fool. If you spot any comments that are unsuitable hit the flag to alert our moderators.

ANuvver 14 Nov 2012 , 11:14am

Might be an idea to mention that GSK is ex-div today.

Now if only the white coats could come up with a treatment to wean MF off its Woodford addiction...

Curvedair 14 Nov 2012 , 7:32pm

I can't reconcile your dividend figures with the correct ones for GSK. Whether yours are per calendar year or UK tax year, they aren't correct for any of the years that you mention from 07 to 11.

Also I am not sure where you get your full year dividend forecast of 78.22p per share from. The 2012/13 tax year total div is 78p which includes a special div of 5p.

KevinGodbold 15 Nov 2012 , 10:34am

Hello Curvedair,

Thanks for your interest in the article.

The information came from www.digitallook.com

Why do think the dividend figures are incorrect?

Best wishes,

Kevin

F958B 15 Nov 2012 , 11:32am

GSK's website-based dividend calculator is here:

http://www.gsk.com/investors/shareholder-information/dividend-calculator.html

2012:
Q3: 18.0p
Q2: 17.0p
Q1: 17.0p


2011:
Q4 Special: 5.0p
Q4: 21.0p
Q3: 17.0p
Q2: 16.0p
Q1: 16.0p

2010:
Q4: 19.0p
Q3: 16.0p
Q2: 15.0p
Q1: 15.0p

2009:
Q4: 18.0p
Q3: 15.0p
Q2: 14.0p
Q1: 14.0p

2008:
Q4: 17.0p
Q3: 14.0p
Q2: 13.0p
Q1: 13.0p

2007:
Q4: 16.0p
Q3: 13.0p
Q2: 12.0p
Q1: 12.0p

Basically a trend of adding a penny to each quarterly dividend each year.
Q3 dividend a penny more than the Q1/Q2, and Q4 dividend34p more than the Q3.


F958B 15 Nov 2012 , 11:33am

Oops thought I'd got rid of that typo - should have said:

"Q4 dividend 4p more than the Q3"

Curvedair 15 Nov 2012 , 6:11pm

Please accept my apologies Kevin. I was looking at them by tax year or calendar year rather than GSK's accounting year.

KevinGodbold 15 Nov 2012 , 7:02pm

No problem Curvedair.

I'm glad you raised the point because mistakes do creep into articles every so often.

Foolish best,

Kevin

Join the conversation

Please take note - some tags have changed.

Line breaks are converted automatically.

You may use the following tags in your post: [b]bolded text[/b], [i]italicised text[/i]. All other tags will be removed from your post.

If you want to add a link, please ensure you type it as http://www.fool.co.uk as opposed to www.fool.co.uk.

Hello stranger

To add your own comment, please login.

Not yet registered? Register now.